Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Shreya Nayak

Neurology Crestview Hills, KY Medical Doctor

NPI 1144614025 CMS profile 2793492

2670 Chancellor Dr, Crestview Hills, KY 41017

Open in the dashboard

General payments

$3,288

131 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Shreya Nayak of Crestview Hills, KY is reported in the CMS Open Payments database as having received $3,288 across 131 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 61st percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $362 17
2024 General $1,014 35
2023 General $741 31
2022 General $444 21
2021 General $335 21
2020 General $42 3
2019 General $349 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Shreya Nayak
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Shreya Nayak were reported at $362. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Shreya Nayak Neurology median Middle half National median
2019 $349 $474 $118–$2,177 $163
2020 $42 $367 $82–$2,309 $114
2021 $335 $438 $104–$2,547 $132
2022 $444 $442 $103–$2,388 $149
2023 $741 $464 $119–$2,312 $160
2024 $1,014 $468 $119–$2,323 $164
2025 $362 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Biogen, Inc. $656 19 payments
  2. AbbVie, Inc. $467 19 payments
  3. SK Life Science, Inc. $372 18 payments
  4. Jazz Pharmaceuticals Inc. $233 12 payments
  5. Novartis Pharmaceuticals Corporation $227 6 payments
  6. Vanda Pharmaceuticals Inc. $169 3 payments
  7. TG Therapeutics, Inc. $163 3 payments
  8. Teva Pharmaceuticals USA, Inc. $127 6 payments
  9. Genzyme Corporation $108 1 payment
  10. Amneal Pharmaceuticals LLC $106 8 payments
  11. Other $659 36 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,288 131 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $361 12 payments
  2. QULIPTA $301 7 payments
  3. Epidiolex $250 13 payments
  4. XCOPRI $240 2 payments
  5. VUMERITY Neurology $218 9 payments
  6. TYSABRI $187 7 payments
  7. PONVORY $169 3 payments
  8. BRIUMVI $163 3 payments
  9. LUMIZYME $108 1 payment
  10. VUMERITY Neurology $106 2 payments
  11. Other $1,142 64 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 31 drugs

Part D claims

1,091

Median for Neurology: 833

Drug cost

$339,460

Median for Neurology: $202,670

Branded share of claims

36.9%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Plegridy Pen Peginterferon Beta-1a Brand 13 $103,190
Emgality Pen Galcanezumab-Gnlm Brand 83 $64,786
Qulipta Atogepant Brand 29 $55,062
Briviact Brivaracetam Brand 15 $31,709
Ubrelvy Ubrogepant Brand 24 $29,105
Aimovig Autoinjector Erenumab-Aooe Brand 21 $27,261
Levetiracetam Generic 138 $4,759
Carbamazepine Er Carbamazepine Brand 19 $4,677
Fingolimod Fingolimod Hcl Brand 12 $2,514
Carbidopa-Levodopa Carbidopa/Levodopa Brand 79 $2,155

The 10 drugs with the highest cost, of 31 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$32,036

Medicare's payments for the services billed

Medicare patients

228

Average age 72

Services billed

485

144 women, 84 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Depression 39%
Diabetes 33%
Ischemic heart disease 32%
Chronic kidney disease 28%
Alzheimer's or dementia 24%
Osteoporosis 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 19 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BRIUMVI
  • TG Therapeutics, Inc. $141
$141 — —
PONVORY
  • Vanda Pharmaceuticals Inc. $123
$123 — —
XCOPRI
  • SK Life Science, Inc. $121
$121 — —
VUMERITY
  • Biogen, Inc. $106
$106 — —
Epidiolex
  • JAZZ PHARMACEUTICALS INC. $95
$95 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 19 in the dashboard with a free account

Records

131 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record